MDT

83.54

+0.49%↑

VEEV

220.44

+2.83%↑

A

105.88

+3.19%↑

WBA

10.99

+0.18%↑

CHE

584.5

+1.44%↑

MDT

83.54

+0.49%↑

VEEV

220.44

+2.83%↑

A

105.88

+3.19%↑

WBA

10.99

+0.18%↑

CHE

584.5

+1.44%↑

MDT

83.54

+0.49%↑

VEEV

220.44

+2.83%↑

A

105.88

+3.19%↑

WBA

10.99

+0.18%↑

CHE

584.5

+1.44%↑

MDT

83.54

+0.49%↑

VEEV

220.44

+2.83%↑

A

105.88

+3.19%↑

WBA

10.99

+0.18%↑

CHE

584.5

+1.44%↑

MDT

83.54

+0.49%↑

VEEV

220.44

+2.83%↑

A

105.88

+3.19%↑

WBA

10.99

+0.18%↑

CHE

584.5

+1.44%↑

Search

Recursion Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

5.72 2.88

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.53

Max

6.09

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-83M

-179M

Pardavimai

-22M

4.5M

Pelnas, tenkantis vienai akcijai

-0.53

Pelno marža

-3,965.994

Darbuotojai

800

EBITDA

-77M

-165M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+61.74% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

2.2B

Ankstesnė atidarymo kaina

2.84

Ankstesnė uždarymo kaina

5.72

Naujienos nuotaikos

By Acuity

50%

50%

172 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Recursion Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-22 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Union Says Nippon Steel Can't Be Trusted With Buying U.S. Steel

2025-04-22 20:55; UTC

Uždarbis

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

2025-04-22 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise After Wall Street Rally -- Market Talk

2025-04-22 23:49; UTC

Rinkos pokalbiai

Gold Falls on Signs of Easing U.S.-China Tensions, Possible Profit-Taking -- Market Talk

2025-04-22 23:47; UTC

Svarbiausios naujienos

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 4th Update

2025-04-22 23:08; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: No Change to Annual Guidance

2025-04-22 23:07; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Assessing Impacts of Recent Tariff Announcements on Louisiana LNG

2025-04-22 23:07; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Advancing Talks Targeting Further Equity Selldown in Louisiana LNG

2025-04-22 23:06; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Trion Project 26% Complete, on Track for First Oil in 2028

2025-04-22 23:05; UTC

Įsigijimai, susijungimai, perėmimai

Woodside: Scarborough Energy Project on Track for First LNG Cargo in 2H 2026

2025-04-22 23:05; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy: Scarborough Energy Project 82% Complete

2025-04-22 23:05; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy: Beaumont New Ammonia Project on Track to Start in 2H

2025-04-22 23:05; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy: Beaumont New Ammonia Project 90% Complete

2025-04-22 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy: Share of Sangomar Production Maintained at 78 Million Bbl/Day in 1Q

2025-04-22 23:04; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Macquarie Set for A$500 Million Gain on Sale From Nomura Deal -- Market Talk

2025-04-22 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Sold 25.4% of Produced LNG at Prices Linked to Gas Hub Indices in 1Q

2025-04-22 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy Cites Lower Output, Reduced Oil-Linked Prices for Revenue Fall

2025-04-22 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy 1Q Revenue Down 5% on Prior Quarter

2025-04-22 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy 1Q Revenue US$3.315 Billion

2025-04-22 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Cites Weather Impacts at North West Shelf, Pluto Unplanned Outages in 1Q

2025-04-22 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy 1Q Oil, Natural Gas Output Down 4% on Prior Quarter

2025-04-22 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Woodside Energy 1Q Oil, Natural Gas Output 49.1 Million BOE

2025-04-22 22:31; UTC

Uždarbis

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- Update

2025-04-22 22:26; UTC

Svarbiausios naujienos

Trump Is Laying the Groundwork to Blame Powell for Any Downturn -- Update

2025-04-22 22:16; UTC

Svarbiausios naujienos

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 3rd Update

2025-04-22 22:16; UTC

Rinkos pokalbiai

Turkey Remains on Course for Steadily Lower Inflation, Finance Minister Says -- Market Talk

2025-04-22 22:04; UTC

Svarbiausios naujienos

China Tariffs 'Won't Be Anywhere Near' 145%: Trump -- Barrons.com

2025-04-22 21:42; UTC

Uždarbis

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- WSJ

2025-04-22 21:21; UTC

Svarbiausios naujienos
Uždarbis

Tesla Profit Sinks, Hurt by Political Backlash -- 3rd Update

2025-04-22 21:19; UTC

Svarbiausios naujienos

Investors Hope for No Surprises as Boeing Reports Earnings -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Recursion Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

61.74% į viršų

12 mėnesių prognozė

Vidutinis 8.75 USD  61.74%

Aukščiausias 11 USD

Žemiausias 6 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Recursion Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

5.51 / 5.64Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

172 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.